• Customer Care
  • (888) 123-4567


Rise Therapeutics is recruiting a full-time molecular biologist to lead its synthetic biology initiatives at our Rockville, Maryland laboratory. This position offers a unique opportunity for an entrepreneurial minded scientist to advance the skills and experience necessary for a successful career in the biotechnology industry. The molecular biologist will support research and development strategies that harness new microbiome discoveries to create novel and innovative synthetic biology-based medicines.

Required Qualifications

  • Degree (MS and/or PhD) in the life sciences, biotechnology, biochemistry, microbiology, biomedical engineering, or equivalent
  • Expertise in molecular biology techniques
  • Solid understanding microbiological science
  • Strong knowledge of prokaryotic genetics
  • Understanding of microbial metabolism
  • Familiarity with bacterial genome modification approaches
  • Strong writing skills
  • Effective communication skills with the ability to contribute in a fast-paced environment
  • Strong sense of responsibility for deadlines and data accuracy
  • Rigor and attention to detail including laboratory notebook documentation
  • Comfort with collaboration in a team-based environment

Duties and Responsibilities

  • Lead new drug development strategies for synthetic biology-based cellular medicines
  • Develop and characterize novel microbiome drug candidates
  • Perform analytical testing procedures for product characterization
  • Develop new microbiology genetic modification systems and scientific assessment procedures
  • Analyzing data to identify limitations and bottlenecks in the performance of your microbes and designing strains in silico based on the above
  • Support discovery and development of new functionally-directed bacteria strains
  • Author SOPs, reports, and other controlled documents important for IND filings


  • Support initiatives to develop novel microbiome-associated products
  • Gain experience working in biotech helping to drive new medicines into clinical testing
  • Expand relationships/connections with leading biotechnology researchers


About Rise Therapeutics

Rise Therapeutics is an emerging, privately held company located in Rockville, Maryland which leverages its expertise in synthetic biology and immunological drug development to create novel cellular-based immune therapies. With a strong emphasis on product development and its internal clinical GMP manufacturing infrastructure, Rise is focused on developing immunological-based biological medicines using a unique and proprietary oral biologics delivery platform. Our drug development focus is driven by new microbiome-related discoveries enabling development of targeted, first-in-class immune modulatory drugs for the treatment of inflammation, autoimmunity, cancer, and infection. In the context of its expertise in synthetic biology medicine, proprietary TPX oral drug delivery platform, and clinical GMP manufacturing capabilities, Rise is creating and rapidly advancing life changing cellular-based medicines to the market. For more information, go to www.risetherapeutics.com.  


Please email your CV or resume to: This email address is being protected from spambots. You need JavaScript enabled to view it.

Our News

Rockville, MD. Rise Therapeutics announced today that they have successfully initiated operations of their GMP manufacturing facility based in Rockville, MD.  Funding to help set up this GMP manufacturing operation came from the National Institute of Health (NIH) Commercialization Readiness Pilot (CRP) Program Grant, which assists small businesses with technical assistance and late-stage development projects that are not typically supported by SBIR and STTR Phase II and Phase IIB grants. Launching of operations for this facility was also supported by the financial contributions of the Montgomery County Economic Development Corporation.  

Rockville, MD. Rise Therapeutics, a company that develops innovative immune therapies, announced today that it initiated a new program to develop a novel, immunologically enhanced microbiome drug for the treatment of cancer. This product candidate, R-5780, engages key immune pathways regulated by the microbiome to enhance the effectiveness of immune checkpoint inhibitor (ICI) therapy to treat cancer. Coinciding with the timing of this release, Rise has secured funding to support key product development initiatives for the program.

Rockville, MD. Rise Therapeutics, a biotechnology company developing first-in-class targeted immunological-based biologics using a unique and proprietary oral delivery platform, announced today the publication of the co-authored article, “Lactococcus lactis Delivery of Surface Layer Protein A Protects Mice from Colitis by Re-Setting Host Immune Repertoire” in the journal Biomedicines.